

# Lambert-Eaton Myasthenic Syndrome

[View the current Lambert-Eaton Myasthenic Syndrome InDepth page on BioPortfolio.com](http://www.bioportfolio.com/indepth/Lambert-Eaton_Myasthenic_Syndrome.html)  
([http://www.bioportfolio.com/indepth/Lambert-Eaton\\_Myasthenic\\_Syndrome.html](http://www.bioportfolio.com/indepth/Lambert-Eaton_Myasthenic_Syndrome.html))

## Recent Publications on Lambert-Eaton Myasthenic Syndrome:



- [Lambert-Eaton myasthenic syndrome differential reactivity of tumor versus non-tumor patients to subunits of the voltage-gated calcium channel.](#)  
*OBJECTIVE: Lambert-Eaton myasthenic syndrome (LEMS) is an autoimmune...*24th September, 2008  
Institute for Clinical Neuroimmunology, Klinikum Grosshadern, Ludwig- J Neuroimmunol. 2008 Sep 20. ([DOI Direct Link](#))
- [Screening for small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome.](#)  
*PURPOSE: A small-cell lung carcinoma (SCLC) is found in 50% of patients...*23rd September, 2008  
Department of Neurology, Leiden University Medical Center, PO Box 9600,- J Clin Oncol. 2008 Sep 10;26(26):4276-81. ([DOI Direct Link](#))
- [Lambert-Eaton myasthenic syndrome: tumor versus nontumor forms.](#)  
*Half the patients with Lambert-Eaton myasthenic syndrome (LEMS) have a...*9th September, 2008  
Department of Neurology, K5-Q, Leiden University Medical Center, PO Box- Ann N Y Acad Sci. 2008;1132:129-34. ([DOI Direct Link](#))
- [Autoimmune channelopathies: John Newsom-Davis's work and legacy A summary of the Newsom-Davis Memorial Lecture 2008.](#)  
*John Newsom-Davis was a key figure in the field of neuroimmunology and...*30th August, 2008  
Department of Clinical Neurology, University of Oxford, Max Plank- J Neuroimmunol. 2008 Sep 15;201-202:245-9. Epub 2008 Aug 22. ([DOI Direct Link](#))
- [Using immunoglobulins in muscular disease treatment.](#)  
*BACKGROUND: Intravenous immunoglobulins (IVIg) have been proven in the...*30th August, 2008  
Department of Neurology, Hannover Medical School, Carl-Neuberg-Street 1,- Expert Opin Biol Ther. 2008 Aug;8(8):1143-50. ([DOI Direct Link](#))
- [Monozygous twins with neuromuscular transmission defects at opposite sides of the motor endplate.](#)  
*Disorders affecting the postsynaptic side of the neuromuscular junction...*8th August, 2008  
Department of Clinical Neurophysiology, Uppsala University Hospital,- Acta Neurol Scand. 2008 Aug 5. ([DOI Direct Link](#))
- [Paraneoplastic neurological autoimmunity and survival in small-cell lung cancer.](#)  
*The autoimmune disorder of Lambert-Eaton myasthenic syndrome (LEMS)...*1st August, 2008  
Department of Neurology, Queen's Medical Centre, Nottingham NG7 2UH,- J Neuroimmunol. 2008 Sep 15;201-202:159-62. Epub 2008 Jul 29. ([DOI Direct Link](#))
- [\[Therapeutic algorithm\]](#)  
*Therapeutic algorism for myasthenia gravis (MG) and myasthenic syndrome...*30th July, 2008

Department of Neurology and Neuroscience, Okayama University Graduate- Nippon Rinsho. 2008 Jun;66(6):1155-7.

- [Lambert-Eaton myasthenic syndrome: Search for alternative autoimmune targets and possible compensatory mechanisms based on presynaptic calcium homeostasis.](#)  
*The Lambert-Eaton myasthenic syndrome (LEMS) is a disease of neuromuscular...*26th July, 2008  
Neurological Center, Kanazawa-Nishi Hospital and Kanazawa University,- J Neuroimmunol. 2008 Sep 15;201-202:145-52. Epub 2008 Jul 24. ([DOI Direct Link](#))
- [A relative weak leg muscle in the rolling Nagoya mouse as a model for Lambert-Eaton myasthenic syndrome.](#)  
*The Lambert-Eaton myasthenic syndrome (LEMS) is caused by auto-antibodies...*26th July, 2008  
Neurophysiology, Department of Molecular Cell Biology, Leiden University- J Neuroimmunol. 2008 Sep 15;201-202:166-71. Epub 2008 Jul 23. ([DOI Direct Link](#))
- [The Lambert-Eaton myasthenic syndrome 1988-2008: A clinical picture in 97 patients.](#)  
*BACKGROUND: Neuromuscular symptoms in patients with Lambert-Eaton...*23rd July, 2008  
Department of Neurology, Leiden University Medical Center, Leiden, The- J Neuroimmunol. 2008 Sep 15;201-202:153-8. Epub 2008 Jul 21. ([DOI Direct Link](#))
- [Chapter 9 The Lambert-Eaton myasthenic syndrome.](#)  
*BACKGROUND: Neuromuscular symptoms in patients with Lambert-Eaton...*18th July, 2008  
Duke University Medical School, Durham, NC, USA.- Handb Clin Neurol. 2008;91:273-83. ([DOI Direct Link](#))
- [Lambert-Eaton myasthenic syndrome in childhood.](#)  
*Lambert-Eaton myasthenic syndrome (LEMS) is a rare autoimmune disorder of...*1st July, 2008  
Department of Neurology, Medical University of Warsaw, Poland.- Eur J Paediatr Neurol. 2008 Jun 26. ([DOI Direct Link](#))
- [Lung adenocarcinoma, dermatomyositis, and Lambert-Eaton myasthenic syndrome: a rare combination.](#)  
*The incidence of lung neoplasms is increasing in Brazil and in the world,...*12th June, 2008  
Francisco Morato de Oliveira Hospital for State Civil Servants - Sao- J Bras Pneumol. 2008 May;34(5):333-6.
- [The potential use of ephedrine in Lambert-Eaton myasthenic syndrome : Clinical and electrophysiological evaluation.](#)  
*Therapeutic algorism for myasthenia gravis (MG) and myasthenic syndrome...*7th June, 2008  
Nerve-Muscle Unit, Neurology service, CHU Vaudois and University of- J Neurol. 2008 Jun 13. ([DOI Direct Link](#))

#### Lambert-Eaton Myasthenic Syndrome Clinical Trials:



- [Treatment of Lambert-Eaton Syndrome With 3,4 DAP](#)  
*Lambert Eaton Myasthenic Syndrome*



## Lambert-Eaton Myasthenic Syndrome Patents:

- 6951924- [Antibodies against secreted protein HTEBYII](#)
- 7078186- [Apoptosis related polynucleotides, polypeptides, and antibodies](#)
- 7091315- [Protein HDPBQ71](#)
- 7112410- [Human tumor necrosis factor TR21 and methods based thereon](#)
- 7138501- [Antibodies that immunospecifically bind BLYS](#)
- 7141547- [Albumin fusion proteins comprising GLP-1 polypeptides](#)
- 7163797- [50 human secreted proteins](#)
- 7164004- [Human tumor necrosis factor TR20 and methods based thereon](#)
- 7175988- [Human G-protein Chemokine Receptor \(CCR5\) HDGNR10](#)
- 7176280- [Isolated polypeptides and compositions from the venom of P. transvaalicus and methods of use](#)
- 7179821- [Method of treating of demyelinating diseases or conditions](#)
- 7070803- [Controlled release pharmaceutical composition for oral use containing midodrine and/or active metabolite, desglymidodrine](#)
- 7067512- [Substituted 1,4-benzodiazepines and uses thereof](#)
- 6967210- [Method of treating of demyelinating diseases or conditions](#)
- 6979547- [Methods for designing specific ion channel blockers](#)
- 6979556- [Separate-cistron constructs for secretion of aglycosylated antibodies from prokaryotes](#)
- 6979724- [Calcium channel proteins](#)
- 6994857- [Albumin fusion proteins](#)
- 7026447- [53 human secreted proteins](#)
- 7026450- [Ma family polypeptides and anti-Ma antibodies](#)
- 7033790- [Proteins and nucleic acids encoding same](#)
- 7041803- [Galectin 11](#)
- 7063950- [Nucleic acids encoding human calcium channel and methods of use thereof](#)
- 7189690- [Albumin fusion proteins](#)
- 7189820- [Antibodies against tumor necrosis factor delta \(APRIL\)](#)
- 7196164- [Secreted protein HHTLF25](#)
- 7354575- [Method and pharmaceutical composition for treating inflammation](#)
- 7354725- [Kinase peptides and antibodies](#)
- 7368527- [HADDE71 polypeptides](#)
- 7368531- [Human secreted proteins](#)
- 7371388- [Treatment of Sjogren's syndrome by administration of TR18 polypeptides](#)
- 7381800- [Antibodies to HBIMF63 polypeptide](#)
- 7390637- [Keratinocyte derived interferon](#)
- 7393934- [Human G-protein chemokine receptor \(CCR5\) HDGNR10](#)
- 7404969- [Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules](#)
- 7411051- [Antibodies to HDPPA04 polypeptide](#)
- 7282484- [Anti-tumor agents](#)
- 7276371- [Stimulation of hematopoietic cells in vitro](#)
- 7205139- [Tissue plasminogen activator-like protease](#)
- 7217788- [Human tumor necrosis factor delta polypeptides](#)
- 7220840- [Antibodies that immunospecifically bind to B lymphocyte stimulator protein](#)

- 7230015- [Method of treating of demyelinating diseases or conditions](#)
- 7232667- [Keratinocyte growth factor-2 polynucleotides](#)
- 7235529- [Brain-associated inhibitor of tissue-type plasminogen activator](#)
- 7238660- [Albumin fusion proteins](#)
- 7238667- [Albumin fusion proteins](#)
- 7241438- [AK155 polypeptides](#)
- 7256002- [Screening for neurotoxic amino acid associated with neurological disorders](#)
- 7414110- [Human calcium channel compositions and methods](#)

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

